News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Incyte
NEWS
JOBS
IN THE PRESS
NEWS
Deals
Rumors Surface M&A-Desperate Gilead is Nearing a Deal to Buy Incyte
March 13, 2017
·
3 min read
Business
Bay Area’s Calithera Biosciences Rockets After Getting $53 Million Upfront in Cancer Deal With Incyte
January 30, 2017
·
2 min read
Deals
Incyte Who? Why This Biotech Would Give Gilead a Bang for Its Buck
January 26, 2017
·
2 min read
Deals
Taking a Shot on Who Might Buy Incyte in 2017
December 27, 2016
·
2 min read
Business
This Biotech Forges $200+ Million Research Pact With Incyte
December 21, 2016
·
3 min read
Deals
Why Incyte, Biogen and BioMarin are Hot Acquisition Targets
October 12, 2016
·
3 min read
Deals
With a Strong Cancer Presence and Pipeline, Incyte Would Make a Sweet Acquisition
July 15, 2016
·
2 min read
Deals
Looking at the Odds, Pfizer, Incyte or Merck & Co. Will Gobble Up Tiny Agenus
June 14, 2016
·
3 min read
Deals
Incyte Buys Ariad’s EU Operations and Iclusig Rights for $140 Million Upfront
May 9, 2016
·
3 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
March 18, 2023
·
16 min read
BioCapital
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
March 14, 2023
·
9 min read
Business
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte’s Oncology Pipeline
March 7, 2023
·
4 min read
BioCapital
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 6, 2023
·
9 min read
Drug Development
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
March 3, 2023
·
3 min read
BioCapital
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
February 24, 2023
·
8 min read
BioCapital
Incyte to Present at Upcoming Investor Conference - February 16, 2023
February 16, 2023
·
1 min read
Drug Development
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
·
9 min read
Business
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
February 7, 2023
·
31 min read
BioCapital
Incyte to Present at Upcoming Investor Conference - January 24, 2023
January 24, 2023
·
1 min read
